Inventiva Sa

IVA

NASDAQ. Currency in USD

3.93 +0.10 ( +2.64% )

Real time prices: September 30

Market Cap.
165.72M
Beta (5Y monthly)
1.10
Price/Earnings
-
EPS (TTM)
-1.31
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
3,538
1y Target Est.
32.33
Day's Range
3.49
-
3.93
52 Week's Range
3.49
-
15.78

Historical Summary

Performance
EPS growth
Share Buybacks

About Inventiva Sa

Sector
Healthcare
Industry
Biotechnology
Website
https://www.inventivapharma.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
40.87M
Employees
101
Address
50 rue de Dijon, Daix, France, 21121
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.

Latest news

Inventiva's NASH Pact In China Represents 'Financially Prudent Pathway,' Says This Analyst
Inventiva's NASH Pact In China Represents 'Financially Prudent Pathway,' Says This Analyst

Last week, Inventiva (NASDAQ: IVA) announced a licensing and collaboration agreement with Sino Biopharm's subsidiary...
By Benzinga - 6 days ago

Dow Turns Higher; Crude Oil Rises 0.7%
Dow Turns Higher; Crude Oil Rises 0.7%

U.S. stocks pared some losses, with the Dow Jones turning higher toward the end of...
By Benzinga - 1 week ago

Why MediWound Is Trading Lower By Around 18%, Here Are 48 Stocks Moving In Thursday's Mid-Day Session
Why MediWound Is Trading Lower By Around 18%, Here Are 48 Stocks Moving In Thursday's Mid-Day Session

Gainers Spero Therapeutics, Inc. (NASDAQ: SPRO) rose 150% to $2.0508 after the company announced it...
By Benzinga - 1 week ago

Nasdaq Drops Over 100 Points; Spero Therapeutics Shares Spike Higher
Nasdaq Drops Over 100 Points; Spero Therapeutics Shares Spike Higher

U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping more than 100...
By Benzinga - 1 week ago

Inventiva reports its 2022 first-half financial results and provides a corporate update
Inventiva reports its 2022 first-half financial results and provides a corporate update

Daix (France), Long Island City (New York, United States), September 22, 2022 – Inventiva (Euronext...
By GlobeNewswire Inc. - 1 week ago

Inventiva publie ses résultats financiers du 1er semestre 2022 et fait un point sur ses activités
Inventiva publie ses résultats financiers du 1er semestre 2022 et fait un point sur ses activités

Daix (France), Long Island City (New York, United States), le 22 septembre – Inventiva (Euronext...
By GlobeNewswire Inc. - 1 week ago

Inventiva et Sino Biopharm signent un accord de licence et de collaboration pour développer et commercialiser lanifibranor en Chine
Inventiva et Sino Biopharm signent un accord de licence et de collaboration pour développer et commercialiser lanifibranor en Chine

Daix (France), Long Island City (New York, Etats-Unis), Beijing/Hong Kong (Chine) le 21 septembre 2022...
By GlobeNewswire Inc. - 1 week ago